Literature DB >> 8296394

Receptor subtypes or species homologues: relevance to drug discovery.

J M Hall1, M P Caulfield, S P Watson, S Guard.   

Abstract

Cell surface receptors are targets for the pharmacological manipulation of physiological processes and thus represent a key direction for the development of selective therapeutic agents. Traditional pharmacological techniques, together with the development of synthetic ligands, have led to the identification of differences in receptor recognition properties and the proposal of multiple receptor subtypes. Molecular biological studies have confirmed the existence of receptor subtypes within a single species by demonstrating differences in receptor primary sequences. However, equivalent receptors between species also show differences in primary structure, albeit to a much lower degree. This review by Judith Hall and colleagues addresses the question of how differences in receptor primary structure between species relate to changes in pharmacology. The relevance of this to the choice of screens in the testing of potential therapeutic drugs is discussed.

Mesh:

Substances:

Year:  1993        PMID: 8296394     DOI: 10.1016/0165-6147(93)90096-3

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  17 in total

1.  Investigation of the specificity of FK 888 as a tachykinin NK1 receptor antagonist.

Authors:  Z Y Wang; S R Tung; G R Strichartz; R Håkanson
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

2.  Antagonism by SR 48692 of mechanical responses to neurotensin in rat intestine.

Authors:  F Mulè; R Serio; A Postorino; T Vetri; F Bonvissuto
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

3.  Inhibition of bradykinin-evoked trigeminal nerve stimulation by the non-peptide bradykinin B2 receptor antagonist WIN 64338 in vivo and in vitro.

Authors:  J M Hall; M Figini; S K Butt; P Geppetti
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

4.  Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro.

Authors:  Anna Siniscalchi; Donata Rodi; Michele Morari; Matteo Marti; Sabrina Cavallini; Silvia Marino; Lorenzo Beani; Clementina Bianchi
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

5.  Characterization of two central AMPA-preferring receptors having distinct location, function and pharmacology.

Authors:  A Pittaluga; S Thellung; G Maura; M Raiteri
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-06       Impact factor: 3.000

6.  Bradykinin promotes neuron-generating division of neural progenitor cells through ERK activation.

Authors:  Micheli M Pillat; Claudiana Lameu; Cleber A Trujillo; Talita Glaser; Angélica R Cappellari; Priscilla D Negraes; Ana M O Battastini; Telma T Schwindt; Alysson R Muotri; Henning Ulrich
Journal:  J Cell Sci       Date:  2016-08-15       Impact factor: 5.285

7.  Pharmacological characterization of bradykinin receptors in canine cultured tracheal smooth muscle cells.

Authors:  C M Yang; S F Luo; H C Hsia
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

8.  Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig.

Authors:  O Piot; J Betschart; I Grall; S Ravard; C Garret; J C Blanchard
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

9.  Bradykinin B2 receptors and coupling mechanisms in the smooth muscle of the guinea-pig taenia caeci.

Authors:  J L Field; S K Butt; I K Morton; J M Hall
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

10.  Characterization of kinin receptors modulating neurogenic contractions of the mouse isolated vas deferens.

Authors:  J Maas; G A Rae; J P Huidobro-Toro; J B Calixto
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.